Section Arrow
BNTC.NASDAQ
- Benitec Biopharma
Quotes are at least 15-min delayed:2025/11/16 04:42 EST
Regular Hours
Last
 13.16
+0.01 (+0.08%)
Day High 
13.29 
Prev. Close
13.15 
1-M High
16.76 
Volume 
226.25K 
Bid
12.58
Ask
13.5
Day Low
12.57 
Open
13.02 
1-M Low
11.535 
Market Cap 
442.65M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 14.12 
20-SMA 15.07 
50-SMA 14.47 
52-W High 17.15 
52-W Low 9.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.05/-8.37
Enterprise Value
443.15M
Balance Sheet
Book Value Per Share
2.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 04:42 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.